News

Life’s Essential 8 scores are substantially lower among adults aged ≥65 years who exhibit high blood pressure, stroke, or other cardiovascular diseases.

Intercept Pharmaceuticals has voluntarily withdrawn obeticholic acid from the US market following a request from the FDA.

These data indicate that greater maternal dietary diversity during pregnancy may be linked with a diminished risk of atopic dermatitis during early childhood.

In addition to type 1 and 2 diabetes, diabetic retinopathy substantially increases the risk of developing and worsening uveitis.

This study compared a recent risk prediction tool for invasive melanoma and its performance compared to existing prediction tools.

Saggese describes recent evolutions in MASH care with the FDA approval of semaglutide and the continued importance of diet, physical activity, and weight management.

A technology review from the University of Virginia analyzes the successes of AID devices, as well as indicating where the technology still has to go.

Brogan explains how to navigate the complexities of the Crohn’s disease treatment landscape and why patients need to be included in the decision making process.

These data underscore the value of individualized cancer risk evaluations when selecting treatment strategies for psoriasis.

Baseline emphysema detected in low-dose CT scans predicts long-term mortality in asymptomatic adults.

In the final segment of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 6 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 5 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 4 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 3 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 2 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 1 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

A look at 13 phase 2 and phase 3 studies with significant implications from EADV 2025's late-breaking sessions.

McCarty explains progress made with new screening options but emphasizes ongoing barriers hindering screening goals and how they need to be addressed.

Wang and colleagues analyzed data from nearly 105,000 patients to create and test a device that can predict the efficacy of various drug combinations for hypertension.

Skarbinski explains challenges providers face when managing refractory GERD and common misconceptions about its diagnosis and treatment.

Regeneron's innovative antibody therapies show promising results in alleviating cat and birch allergies.

Preliminary topline results have been released from the ASCEND study on rocatinlimab in adults and adolescents with atopic dermatitis.

For the first time, the FDA has accepted the initiation of the qualification of an NIT as a noninvasive surrogate endpoint in drug development for MASH.

Investigators systematically reviewed NB-UVB treatment responses for psoriasis in patients with skin of color.

Intralesional triamcinolone showed significantly greater hair regrowth and patient satisfaction.

Moore describes recent progress in PBC and PSC and how this defined the field of hepatology in 2024, with lasting effects into 2025.